Date | Price Target | Rating | Analyst |
---|---|---|---|
11/9/2023 | Outperform → In-line | Evercore ISI | |
11/9/2023 | Buy → Neutral | H.C. Wainwright | |
11/9/2023 | $31.00 → $1.00 | Buy → Neutral | Mizuho |
7/20/2022 | $8.00 → $3.00 | Neutral → Sell | Citigroup |
7/13/2022 | $10.00 | Overweight → Neutral | JP Morgan |
7/13/2022 | $16.00 → $5.00 | Buy → Hold | Stifel |
5/10/2022 | $15.00 → $8.00 | Buy → Neutral | Citigroup |
1/3/2022 | $26.00 → $27.00 | Overweight | JP Morgan |
4 - Atara Biotherapeutics, Inc. (0001604464) (Issuer)
4 - Atara Biotherapeutics, Inc. (0001604464) (Issuer)
4 - Atara Biotherapeutics, Inc. (0001604464) (Issuer)
4 - Atara Biotherapeutics, Inc. (0001604464) (Issuer)
4 - Atara Biotherapeutics, Inc. (0001604464) (Issuer)
4 - Atara Biotherapeutics, Inc. (0001604464) (Issuer)
SC 13G/A - Atara Biotherapeutics, Inc. (0001604464) (Subject)
SC 13D - Atara Biotherapeutics, Inc. (0001604464) (Subject)
SC 13G - Atara Biotherapeutics, Inc. (0001604464) (Subject)
10-Q - Atara Biotherapeutics, Inc. (0001604464) (Filer)
8-K - Atara Biotherapeutics, Inc. (0001604464) (Filer)
8-K - Atara Biotherapeutics, Inc. (0001604464) (Filer)
Pierre Fabre Laboratories to License Commercialization Rights to Tab-cel®, including Regulatory, Manufacturing and Development Activities, in the United States and All Remaining Markets Atara to Receive Additional Payments of up to USD 640 Million, Significant Double-digit Tiered Royalties as a Percentage of Net Sales, and Funding of Tab-cel Global Development Costs Tab-cel Global Partnership and Associated Strategic Restructuring Extends Atara Cash Runway into Q3 2025 ATA188 Phase 2 EMBOLD Study Primary Analysis and Communication on Track for Early November Atara to Host Conference Call and Webcast today at 6:00 a.m. PDT / 9:00 a.m. EDT Atara Biotherapeutics, Inc. (NASDAQ:ATRA),
Atara Biotherapeutics, Inc. (NASDAQ:ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the Company will release second quarter 2023 financial results after market close on Tuesday, August 8, 2023. About Atara Biotherapeutics, Inc. Atara is harnessing the natural power of the immune system to develop off-the-shelf cell therapies for difficult-to-treat cancers and autoimmune conditions, including multiple sclerosis, that can be rapidly delivered to patients within days. With cutting-edge science and differentiated approach, At
Atara Biotherapeutics, Inc. (NASDAQ:ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the Company will release first quarter 2023 financial results after market close on Monday, May 8, 2023. About Atara Biotherapeutics, Inc. Atara Biotherapeutics, Inc. (@Atarabio) is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease. With our lead program receiving ma
Evercore ISI downgraded Atara Biotherapeutics from Outperform to In-line
H.C. Wainwright downgraded Atara Biotherapeutics from Buy to Neutral
Mizuho downgraded Atara Biotherapeutics from Buy to Neutral and set a new price target of $1.00 from $31.00 previously
Goldman Sachs analyst Tommie Reerink maintains Atara Biotherapeutics (NASDAQ:ATRA) with a Sell and lowers the price target from $12.5 to $11.
Prescription Drug User Fee Act (PDUFA) Target Action Date of January 15, 2025If Approved, Tab-cel Would Be First Approved Therapy in U.S. for EBV+ PTLDBLA Acceptance Triggers $20 Million Milestone Payment from Pierre Fabre Laboratories, with Additional $60 Million Milestone if Approved by FDA
Eikon Therapeutics, Inc., a California-based biotechnology company that applies advanced engineering and high-performance computing to the identification of important new medicines, today announced the appointment of Roy D. Baynes, MB, BCh, MMed, PhD, as Executive Vice President and Chief Medical Officer, effective July 11, 2022. A gifted physician-scientist and leading oncologist, Dr. Baynes is among the most experienced – and most successful – clinical development leaders in the biopharmaceutical industry. Dr. Baynes will serve as a consultant to Eikon Therapeutics beginning April 1, 2022 before transitioning to his full-time role as Executive Vice President and Chief Medical Officer in J
Atara Biotherapeutics, Inc. (NASDAQ:ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the appointment of Ameet Mallik to the Board of Directors. Mr. Mallik is a biotechnology and pharmaceutical industry expert with a successful track record of bringing innovative oncology therapeutics, including CAR T cell therapy, to market in the U.S. and other countries. With more than 25 years of experience, Mr. Mallik adds relevant and directly applicable management and operational experience that will be instrumental as Atara progresses toward commercial laun
Tab-cel® U.S. BLA Accepted Under Priority Review With PDUFA Action Date of January 15, 2025 ATA3219 Lupus Nephritis and Severe Systemic Lupus Erythematosus Study Initiation Expected Q4 2024; Initial Clinical Data Expected Mid-2025 Enrolling ATA3219 Non-Hodgkin's Lymphoma Study; Initial Clinical Data Expected Q1 2025 Effective September 9, 2024, Pascal Touchon To Assume Role of Chairman of the Board of Directors of Atara; Cokey Nguyen, Ph.D., Currently Chief Scientific and Technical Officer, To Be Appointed President and CEO Cash Runway Into 2027 Enables Key Pipeline Readouts Atara Biotherapeutics, Inc. (NASDAQ:ATRA), a leader in T-cell immunotherapy, leveraging its novel allogenei
Atara Biotherapeutics, Inc. (NASDAQ:ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President and Chief Executive Officer and Cokey Nguyen, Ph.D., Executive Vice President, Chief Scientific & Technical Officer, will participate at the Canaccord Genuity 44th Annual Growth Conference on Wednesday, August 14, 2024 at 8:30 a.m. PDT / 11:30 a.m. EDT. A live webcast of the presentation will be available by visiting the Investors and Media section of atarabio.com. An archived replay of the webcast will be avai
Prescription Drug User Fee Act (PDUFA) Target Action Date of January 15, 2025 If Approved, Tab-cel Would Be First Approved Therapy in U.S. for EBV+ PTLD BLA Acceptance Triggers $20 Million Milestone Payment from Pierre Fabre Laboratories, with Additional $60 Million Milestone if Approved by FDA Atara Biotherapeutics, Inc. (NASDAQ:ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted the filing of its Biologics License Application (BLA) for tabelecleucel (tab-cel®)